Ovarian fibrosis: Mechanistic insights and emerging therapeutic horizons.
Level 5 - mechanism / opinion, no new human data
Narrative review of biological mechanisms without systematic methodology or primary clinical data
PubMed 42008243 · doi:10.1016/j.gene.2024.149190
What was done
This narrative review synthesized the existing literature on the pathophysiology of ovarian fibrosis associated with conditions such as premature ovarian failure, endometrioid cysts, polycystic ovary syndrome, and post-chemoradiotherapy damage. The authors evaluated driving molecular mechanisms—including epigenetic alterations, transcriptional changes, inflammatory pathways, oxidative stress, iron overload, and extracellular matrix remodeling—and reviewed proposed diagnostic approaches and therapeutic targets.
What was found
The abstract reports no empirical data, sample sizes, or quantitative effect estimates. It qualitatively outlines that excessive extracellular matrix accumulation occurs when tissue injury exceeds parenchymal repair capacity, leading to irreversible fibrosis, and summarizes mechanistic pathways to identify prospective precision-targeted therapies.
Why it matters
Ovarian fibrosis impairs female reproductive potential and endocrine function across diverse etiologies. Clarifying molecular pathways provides a conceptual framework for developing targeted antifibrotic therapies and fertility preservation strategies.
Limits
The paper is a non-systematic narrative review providing no primary clinical or experimental data. Search criteria, study selection parameters, and quantitative syntheses are not reported in the abstract.
Cited by
- supports Ovaries of women with premature ovarian insufficiency show increased inflammatory markers, chronic inflammation, and fibrosis.